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Summary 
Serum contains many growth factors and nutrients that stimulate colony formation of hemato- 
poietic progenitor cells  (HPC) in semisolid cultures, In the absence of serum, no proliferation 
of HPCs could be obtained in semisolid medium cultures  of partially purified bone marrow 
cells in the presence of multiple hematopoietic growth factors, insulin, cholesterol, and purified 
clinical-grade human albumin.  This appeared to be due  to a suppressive activity induced  by 
monocyte- and T  lymphocyte-depleted accessory cells  on CD34 + HPCs.  Serum-free condi- 
tioned medium from the bladder carcinoma cellline 5637  could replace serum to support the 
growth of HPCs in these cultures. After gel filtration and reverse-phase high-performance liq- 
uid chromatography of 5637 supernatants, this activity could be attributed to a 15-kD protein 
that was further identified by NH2-terminal sequence analysis as the serine proteinase inhibitor 
antileukoproteinase  (ALP).  The  growth-supportive activity from the  5637  conditioned  me- 
dium and the (partially)  purified fractions could be completely neutralized by a polyclonal rab- 
bit  IgG antibody against human  ALP  (huALP).  Similar supportive  effects on  the  growth  of 
HPC  could be obtained in  the presence of recombinant huALP.  We demonstrated  that  the 
COOH-terminal domain of ALP containing the proteinase inhibitory activity was responsible 
for this effect, o~-1 proteinase inhibitor was capable of similar support of in vitro HPC growth. 
These results illustrate that proteinase inhibitors play an important role in the in vitro growth of 
hematopoietic ceils  by the neutralization  of proteinases produced by bone marrow accessory 
cells.  This may be of particular relevance for in vitro expansion of human hematopoietic stem 
cells in serum-free media. 
C 
haracterization of hematopoiesis in humans is depen- 
dent on the in vitro analysis of hematopoietic progen- 
itor cells (HPC) 1. HPCs can be studied using semisolid me- 
dium  cultures,  and  their  potential  for  proliferation  and 
differentiation can be characterized by their ability to form 
IAbbreviations used in this  paper: oe-1 PI, or-1 proteinase inhibitor; ALP, an- 
tileukoproteinase; bFGF, basic fibroblast growth factor; BFU-E, burst- 
forming unit erythroid colony; CM, conditioned medium; CPG, con- 
trolled pore glass; EGF, epidermal growth factor; EPO, erythropoietin; 
GCSF, granulocyte colony stimulating factor; GM, granulocyte macro- 
phage; HGF, hematopoietic  growth factor; HPC, hematopoietic  progen- 
itor cell; HSA, human serum albumin; huALP, human antileukoprotein- 
ase; IGF, insulin-like growth factor; PDGF, platelet-derived growth 
factor; rALP, recombinant human antileukoproteinase; RP-HPLC, re- 
verse-phase HPLC; SCF, stem cell factor; TFA, trifluroacetic acid. 
colonies  of  hematopoietic  cells  in  these  cultures.  The 
growth and differentiation of HPC in colony assays depend 
on the presence of hematopoietic growth factors (HGF) in 
the cultures  (1).  These HGF may be added to the culture 
medium  or produced  by accessory cells  or HPC  as para- 
crine or autocrine growth factors, respectively. In addition, 
factors that are present in serum, including insulin,  choles- 
terol,  or  albumin,  are  critical  for  the  in  vitro  growth  of 
HPC (2-7). BSA, frequently used as a source of albumin, is 
usually not  >95-99%  pure because of its  strong protein- 
binding properties (8, 9). Since in serum-free colony assays, 
BSA is often used at relatively high concentrations, residual 
undefined  proteins  may  significantly  contribute  to  the 
growth-supportive  potential  of BSA.  Pilot  studies  in  our 
laboratory indicated that in contrast to these BSA prepara- 
tions, highly purified concentrates of clinical-grade human 
albumin  did  not  support  the  proliferation  of HPC  from 
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marrow cells in semisolid medium cultures in the presence 
of HGF, cholesterol, and insulin. In this study, we analyzed 
the  mechanisms  of this finding and  showed  that  this  was 
due  to  a  suppressive  effect of monocyte-  and  T  lympho- 
cyte-depleted bone marrow accessory cells on CD34-puri- 
fled HPC. We investigated which serum factor, in addition 
to human albumin, insulin, and cholesterol, was responsible 
for supporting the in vitro proliferation of bone  marrow- 
derived HPC.  We  found  that  a  15-kD  protein present in 
conditioned  medium  (CM)  from  the  bladder  carcinoma 
cell line 5637 could replace serum. This protein was identi- 
fied  as  the  serine  proteinase  inhibitor antileukoproteinase 
(ALP). 
Materials  and Methods 
Cell Preparations.  After informed consent, bone marrow sam- 
ples were obtained from healthy donors. The  cells were centri- 
fuged on Ficoll Isopaque (density 1.077  g/cm  3, 20 min, 1,000 g), 
and mononuclear cells were depleted of monocytes and T  lym- 
phocytes as described previously (10). These enriched bone mar- 
row  samples were  cryopreserved and stored in liquid nitrogen. 
hnmediately before use, the cells were thawed rapidly in a water 
bath of 37~  washed once in cold (0~  RPMI-1640  medium 
(Hyclone Labs.,  Logan, UT)  supplemented with 20%  (vol/vol) 
fetal  bovine  serum  (Boehringer,  Mannheim,  Germany),  and 
twice with cold RPMI-1640  medium supplemented with 0.1% 
(wt/vol) clinical grade human serum albumin (HSA; Central Lab- 
oratory of the Bloodtransfusion Services, Amsterdam, The Neth- 
erlands).  The cells were resuspended in IMDM (Hyclone Labs.) 
supplemented with  0.1%  (wt/vol)  HSA.  In some  experiments, 
highly purified CD34 + cells were  isolated from the monocyte- 
and T lymphocyte-depleted  bone marrow cells. The CD34 + cells 
were either selected after staining with FITC-conjugated CD34- 
specific  mAbs  (HPCA-2;  Becton  Dickinson,  Mountain  View, 
CA) and sorted with a FACStar  |  PLUS  (Becton Dickinson) or 
isolated after incubation with magnetic Dynabeads M-450 (Dynal 
Inc., Lake Success,  NY)  coated with a primary antibody specific 
for the CD34 Ag. After magnetizing the CD34 + cells, the non- 
binding population was harvested as the CD34  accessory cells. 
The  CD34 + cells were recovered after incubation with a sheep 
polyclonal antibody anti-CD34  Fab  IgG  (Detachabead  CD34; 
Dynal Inc.), resulting in >80% pure CD34 + cells. 
Cytokines and Antibodies.  All cytokines used in this study were 
recombinant human proteins and used at plateau concentration to 
induce optimal colony growth. The cytokines and final concen- 
trations used were: stem cell factor (SCF)  (50  ng/ml),  granulo- 
cyte-colony stinmlating factor (G-CSF) (10  ng/ml), basic fibro- 
blast growth  factor  (bFGF)  (10  ng/ml),  and  epidermal growth 
factor (EGF)  (10  ng/ml)  provided by Amgen (Thousand Oaks, 
CA); IL-3 (50 ng/ml), IL-11  (10 ng/ml), monocyte-CSF (1,000 
U/ml), and GM-CSF (10 ng/ml) were provided by Genetics In- 
stitute  (Cambridge,  MA);  IL-lc~ (10  ng/ml),  IL-5  (10  ng/ml), 
and IL-12 (10 ng/ml) were gifts from Hoffman La Roche (Nut- 
ley, NJ);  IL-4 (500  U/ml)  and IL-7 (10 ng/ml) were gifts from 
hnmunex  Corporation (Seattle, WA); IL-6 (1  ng/ml)  and IL-8 
(10 ng/ml) were gifts from Sandoz (Basel, Switzerland); platelet- 
derived  growth  factor  (PDGF;  30  ng/ml)  was  obtained  from 
GIBCO  BRL  (Gaithersburg,  MD);  insulin-like growth  factors 
(IGF-I, IGF-II, 250  ng/ml) were obtained from Genzyme Cor- 
poration (Cambridge, MA); and erythropoietin (EPO) (1 1U/ml) 
was a gift from Cilag (Herentals, Belgium).  IL-9  (1,000  U/ml) 
was  provided by  Ludwig  Institute  for  Cancer,  (Brussels,  Bel- 
gium),  IL-10  (10  ng/ml)  was  obtained  from  Schering-Plough 
Research Institute (Kenilworth, NJ), and IL-2 (300 U/ml) was a 
gift from Roussel Uclaf (Paris, France). Recombinant human an- 
tileukoproteinase (rALP) was a generous gift from Dr. R.C. Thomp- 
son (Synergen Inc., Boulder, CO). The separated NHa-tenninal 
and the COOH-terminal domains of ALP, designated ALP-D-1 
and ALP-D-2, respectively, were kindly donated by I)r. G. Stef- 
fens (Grtinentahl, Aachen, Germany) and were used at equivalent 
molar concentrations ofrALP, er  proteinase inhibitor (0r  PI), 
used at a final concentration of 0.2  to 20  Ixg/ml, was  obtained 
from Cutter Biologic (Hartford, CT). A neutralizing anti-human 
antileukoproteinase (huALP)  antibody was  prepared in  rabbits. 
The antibody has been found to have a high titer and specificity 
for huALP (11). 
Clonogenic Assay.  Semisolid medium cultures were perfomaed in 
sixfold in  flat-bottomed 96-well  microtiterplates (Greiner,  A1- 
phen a/d Rijn, The Netherlands) in aliquots of 0.1  ml per well, 
containing 103 monocyte- and T lymphocyte--depleted  mononu- 
clear bone  marrow cells  or  150  purified CD34 §  cells per well. 
The  culture  medimn  consisted of IMDM,  supplemented with 
0.6%  (wt/vol)  HSA,  20  Ixg/ml  cholesterol  (Sigma  Chemical 
Company,  St.  Louis, MO;  C-7402),  10  txg/ml insulin  (Signna 
1-4011),  5  X  10 `5  M  ~-mercaptoethanol, (3.47 mg/ml  human 
transferrin  (Behringwerke  AG,  Marburg,  Germany)  saturated 
with FeCI  3 ￿9 6H20,  methylcellulose (Methocel 4000  cps; Fluka, 
Freiburg, Germany) at a final concentration of 1.l% (wt/vol) and 
a mixture of cytokines: GM-CSF (10 ng/ml), G-CSF (10 ng/ml), 
IL-3 (50 ng/ml), SCF (50  ng/ml), and EPO  (1  IU/ml). All cy- 
tokines were  present  at  saturating concentrations.  This  culture 
medium was supplemented either with control medium, hunran 
AB serum from healthy blood donors  (10%  [vol/vol]) that was 
prescreened for alloantibodies and inactivated for 30 rain at 56~ 
or a  CM  produced by the  human  bladder carcinoma cell line 
5637 in the absence of serum, or (partially) purified fractions from 
this CM or proteinase inhibitors. Purified CD34 + cells were cul- 
tured in the absence or presence of increasing numbers ofmono- 
cyte- and T  lymphocyte-depleted bone  marrow accessory cells. 
In some experiments, to neutralize the biologic activity of these 
supplements, a 2-h incubation at 37~  and 5% CO2 in the pres- 
ence of neutralizing concentrations ofanti-huALP antibodies was 
performed before initiation of the bone marrow culture. After 12 d 
of incubation in a fully humified atmosphere of 5% CO 2 at 37~ 
colonies were  counted.  Granulocyte-macrophage colony-form- 
ing units  (CFU-GM) were  defined as aggregates of at least  50 
cells and burst-forming unit  erythroid colonies (BFU-E) as he- 
nmglobinized bursts. To  calculate the HPC  growth in the par- 
tially purified bone marrow fractions, the colony growth induced 
by  the  culture  medium  alone  was  considered background  and 
therefore in these experiments subtracted from the colony growth 
induced by AB serum, CM, or purified CM fraction. BFU-E and 
CFU-GM growth in the presence of 10%  (vol/vol) AB serum 
was considered 100% growth  (control culture).  Colony growth 
was expressed as percentage growth of the control culture. 
Production of CM.  The  human  bladder  carcinoma  cell  line 
5637  (12,  13) was used to produce a serum-free CM.  Confluent 
adherent cells were washed three times with RPMI-1640 and in- 
cubated  for  24  h  in  1KPMI-1640  serum-free  medium,  supple- 
mented with 0.6%  (wt/vol) HSA. Then,  the  cells were washed 
three  times  with  RPMI-1640  and  cultured  in  IMDM,  supple- 
mented with  5  X  10 -s  M  ~-mercaptoethanol and  0.47  mg/ml 
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Figure 1.  Influence of CD34- accessory cells on CFU-GM and BFU-E 
growth of purified CD34 + cells in the presence of multiple HGF (G-CSF 
10 ng/ml, GM-CSF 10 ng/nfl, IL-3 50 ng/ml, SCF 50 ng/ml, EPO  1 
IU/nfl) in the absence and presence of AB serum (10% vol/vol) (n =  2). 
Colony growth  of 150 CD34 + cells plated per well, supplemented with 
increasing numbers of CD34- cells at ratios up to  16:1, is expressed as 
percentage of growth of control culture, obtained in the presence of 10% 
(vol/vol)  AB serum in the  absence of CD34- accessory cells. Absolute 
numbers of colonies in the control culture were 8 +-- 1 CFU-GM and 11 -+ 
1 BFU-E (mean +- SE per 15(:) cells plated). 
human transferrin, saturated with FeCIO  3 ￿9 6H20. After 48 h, the 
culture  supematant was  harvested.  The  crude  supernatant was 
centrifuged (15 rain, 500 g, 20~  irradiated (50 Gy), and frozen 
at -20~  after addition of 0.1% (wt/vol) HSA for stabilization. 
Purification of CM.  Crude supernatant from 5637 cells was in- 
cubated for 2  h  at 4~  with controlled pore  glass  (CPG)  beads 
(PG-350-200;  Sigma)  for  adsorbtion  at  pH  7.0  (14-16).  The 
CPG beads were washed with Dulbecco's modified PBS and 0.01 M 
glycine/HC1, pH  3.5.  The protein fraction was eluted by care- 
fully stirring with 0.3 M  glycine/HC1, pH 2.0  (1/10 of original 
crude  volume), concentrated and neutralized by dialysis  against 
PBS containing 10%  (wt/vol) polyethylene glycol (PEG 20.000) 
(Serva, Heidelberg,  Germany). For further fractionation of pro- 
teins, a gel filtration was performed on Ultrogel ACA 54  (Phar- 
macia, Uppsala, Sweden) by using a 2.6 ￿  100-cm column and a 
flow  rate  of 22  ml/h.  BSA  (Mr  67,000),  OVA  (M  r  45,000), 
chymotrypsinogen (M  r 25,000), and lysozyme (M  r 14,300) were 
used as molecular mass  markers.  5.5-ml fractions were  collected 
by elution with  18%  ethylene glycol buffer in 1.55  M  NaCI,  8 
mM phosphate, pH 7.2. The protein concentration was analyzed 
by  a  Coomassie blue/G-250 binding assay,  using the  Bio-Rad 
(Richmond,  CA)  commercial kit and BSA as a  standard.  Frac- 
tions from the Ultrogel column that could support colony growth 
of HPC  were  supplemented with  Tween  20  (0.01%  vol/vol), 
concentrated on a centricon-3 filter (Amicon Inc., Beverly, MA), 
and  further  fractionated  by  reverse-phase  HPLC  (P,P-HPLC). 
The concentrate was injected on a C8-Aquapore ILP-300 (2.1  ￿ 
220 ram) column (Applied Biosystems Inc., Foster City, CA) and 
equilibrated with 0.1% trifluoroacetic acid (TFA). Proteins were 
eluted at a flow rate of 0.4 ml/nfin with a linear gradient of ace- 
tonitrile (0-80% in 80 min) in 0.1% TFA. 400-p~l fractions were 
collected in tubes containing 0.01% (final concentration) Tween 
20, and the absorption at 220 nm was measured. 
Active P-,P-HPLC fractions, containing low protein concen- 
trations, were analyzed for purity by SDS-PAGE. Samples (20 p,1) 
were loaded onto a polyacrylamide gel (reducing conditions), run 
simultaneously with molecular mass  markers,  and proteins were 
silver stained. The electrophoretically pure fractions were finally 
analyzed on a 477A protein sequencer with on-line detection of 
the phenylthiohydantoin AA in a 120A analyzer (Applied Biosys- 
terns) (17).  Chemical digestion of protein was obtained with 75% 
formic acid at 37~  for 50 h  (17). 
Results 
Influence  of Serum  and  Accessory  Cells  on  HPC  Growth. 
In  cultures  containing  10%  AB  serum  and  HGF  (IL-3, 
GM-CSF,  G-CSF,  SCF,  EPO),  the  absolute  numbers  of 
HPC  per  103 monocyte- and T  lymphocyte--depleted bone 
marrow cells were  21  +  2  CFU-GM  and 20  +  2  BFU-E 
(,  =  8). 
Replacement of AB serum by HSA (0.6% wt/vol), cho- 
lesterol (20 p~g/ml), and insulin (10 ~g/ml) resulted in only 
4  _+  1 GM colonies and no BFU-E growth per 103 mono- 
cyte- and T  lymphocyte-depleted mononuclear bone mar- 
row  cells plated  (background colony growth).  In contrast, 
in  cultures  of purified  CD34 +  cells,  HPC  growth  in  the 
presence of 10% AB serum yielded 16  ---  1  CFU-GM  and 
10  +-  1 BFU-E per 150 cells plated, whereas in the absence 
of AB  serum,  9  +  2  CFU-GM  and  6  -+  1  BFU-E  were 
cultured (n =  10).  Fig.  1 shows that addition of monocyte- 
and T  lymphocyte-depleted CD34-  bone marrow cells to 
purified CD34 +  ceils resulted in a  dose-dependent inhibi- 
tion of HPC  growth  in the  absence, but not in the  pres- 
ence  of AB  serum,  illustrating that  serum contains factors 
capable of supporting HPC  growth in the presence of bone 
marrow accessory cells. 
Influence  of 5637 CM on HPC Growth in the Absence of Se- 
rum.  Replacement  of  AB  serum  by  interleukins  (IL-1 
through  [L-12),  separately  or  in various  combinations, or 
growth factors PDGF, bFGF, EGF, IGF-I, IGF-II, or mac- 
Table 1.  Effect  of 5637 CM on Colony Growth of Monocyte- and 
T Lymphocyte-depleted  Bone Marrow Mononuclear Cells in the 
Absence of Serum 
Colonies per 103 cells 
plated 
Condition  CFU-GM  BFU-E 
Serum-free medium  4  +  1  0 
5637 CM (vol/vol)  10%  28 +  3  17 +  2 
3%  18 -+ 3  13  _+ 3 
1%  9_+2  7_+2 
AB serum (vol/vol)  10%  21  +  2  20 +_ 2 
All cultures were perfomled in the presence of optimal concentrations 
ofHGF (GM-CSF 10 ng/ml, G-CSF 10 ng/ml, IL-3 50 ng/ml, SCF 
50 ng/ml, and EPO 1 IU/ml). 
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Figure  2.  Fractionation of  HPC  growth-promoting activity from 
CPG-purified 5637 CM by gel filtration (Uhrogel ACA 54). The shaded 
area represents the protein concentration per fraction. The growth sup- 
portive activity  for CFU-GM (x-x) and BFU-E ([Z]-lZ])  colonies  from the 
monocyte- and T-lymphocyte depleted bone marrow mononuclear cells 
was analyzed  in the presence of multiple  HGF in the absence  of serum 0l = 
4). Colony g-rowth supported by each colunm fraction at a final concen- 
tration of0.3% was expressed as percentage of growth of control cultures 
in the presence of 10% AB serum. The absolute numbers of colonies in 
the control cuhure were 17 --+ 4 CFU-GM and 20 .+ 4 BFU-E (mean -+ 
SE per 1()  ~ cells plated). Protein concentrations  were determined by the 
Coomassie blue binding  assay. Molecular mass markers: BSA, (M~ 
67,I)00), ovalbmnin (OV, M~ 45,000), chymotrypsinogen (CHYM, M, 
25,i)011), and lysozyme (LYS, M,. 14,300). 
rophage  CSF,  in addition to  the  cytokines present in the 
culture medium, did not result in additive growth of colo- 
nies  from  monocyte-  and  T  lymphocyte-depleted  bone 
marrow  cells  (data  not shown).  However,  addition of 3- 
10% (vol/vol) CM, produced by 5637 cells in the absence 
of serum,  could  support  the  colony growth  up  to  levels 
similar to the growth observed in the presence of 10% AB 
serum.  Replacement of AB serum by  10%  (vol/vol) 5637 
CM  to  the  culture  medium  supported  136  +  12%  of 
CFU-GM growth and 85  +  4% of BFU-E growth as com- 
pared to the control culture. These results show that in the 
presence  of purified hulnan albumin, 5637  cells  produce 
factors  that can support the growth of CFU-GM and BFU-E 
comparable to the effect of AB serum (Table 1). 
Characterization  of the  Supportive  Factor from  5637  CM. 
The protein fraction from the  5637  CM,  concentrated by 
adsorption to and elution froln the CPG beads,  contained 
the colony growth supportive Factor with a fivefold higher 
concentration of activity compared to  the  crude 5637  su- 
pernatant (data not shown). After gel filtration of the CPG- 
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Figure  3.  Purification of HPC  growth-promoting activity by  RP- 
HPLC. In the absence of serum, each P,P-HPLC fraction (400 b~l) was 
analyzed for the supportive  activi  W  ff)r CFU-GM. (x-x) and BFU-E ([Z]-U]) 
growth  from monocyte-  and  T  lymphocyte-depleted bone  marrow 
mononuclear cells in the presence ofHGF (tl = 3). Colony growth sup- 
ported by each fi'action  at a final concentration of 0.3% was expressed as 
percentage of growth of control cultures, obtained in the presence of II)% 
(vol/vol) AB serum. Absolute  numbers of colonies in the control culture 
were 12 -+ 3 CFU-GM and 16 _+ 4 BFU-E (mean .+  SE per 103 cells 
plated). Fraction  f-32 contained the highest level of supportive activity'  for 
both the myeloid  and erythroid colony  growth, 75 .+  12"/, and 121  ,+ 20% 
(mean percentage of growth ,+ SE), respectively. 
eluate into 90 fractions,  the major protein peaks were  re- 
covered from fractions 30 to 40 (>45 kD). As illustrated in 
Fig. 2, addition of0.3% (vol/vol) of these high M r protein- 
containing fractions to the culture medium did not result in 
an enhancement of colony growth.  However, addition of 
0.3% (vol/vol) of low Mr protein fractions 59 through 72, 
containing very low protein concentration (<1-2  ~g/ml) 
supported the growth of both CFU-GM and BFU-E, with 
a maximal level of growth in fractions 62 and 69 containing 
10-15-kD protein. These fractions were chosen for further 
purification by RP-HPLC technique. After HPLC separa- 
tion  of fraction 62,  the  enhancing activity for both  GM- 
colony growth and BFU-E growth was found in fractions 
30-32 (Fig. 3). Fraction 32 supported CFU-GM and BFU-E 
growth  up  to  75  +  12%  and  125  +  20%  of control cul- 
tures, respectively. 
The HPLC fractions, which contained the highest growth 
supportive  activity,  were  electrophoretically  analyzed  for 
purity by  means  of SDS-PAGE,  and  the  molecular mass 
was defined as shown in Fig. 4. The HPLC fractions 30-32 
from  gel  fihration  fraction  62  showed  a  distinct  protein 
band of 15  kD,  with the highest concentration in fraction 
1308  Antileukoproteinase Supports 111 Vitro Hematopoiesis Figure  4.  SDS-PAGE of ILP-HPLC fractions containing biologically 
active (Fig. 3) 15-kD protein from 5637-cell CM. Of each fraction, 20 p~l 
was loaded on a polyacrylamide gel under reducing conditions and pro- 
teins were silver stained. Molecular mass markers (Bin-Rad, Ikichmond, 
CA) were phosphorylase  b (M  r 92,500), BSA (Mr 66,200), ovalbumin (M, 
45,000), carbonic anhydrase (M  r 31,000), soybean trypsin inhibitor (M, 
21,500), lysozyme (M  r 14,400), and the low M, marker aprotinin (Pierce 
Chemical Company, Rockford, 1L) (M  r 6,500). 
32(g32).  An automated protein sequencer was used  to se- 
quence  the first 30  NH2R-terminal amino acid residues of 
the  protein, and they revealed complete structural identity 
with homology to the NH2-terminal sequence of the serine 
proteinase inhibitor ALP. ALP consists of a total of 107 res- 
idues. When purified natural protein was digested with for- 
mic  acid, sequence  analysis of the  internal amino  acids 50 
to  76  showed  again identity to  ALP,  confirming its com- 
plete homology to ALP (Fig. 5). Similarly, the second peak 
of activity from gel filtration (fractions 68 and 69) was puri- 
fied by HPLC,  yielding again a  predominant  15-kD  pro- 
tein  (fraction  28),  which  was  also  identified  as  ALP  by 
NH2-tenmnal  sequence  analysis  (45  residues)  (Fig.  5).  As 
shown  in  Fig.  6,  purified  rALP  could  also  support  the 
growth  of CFU-GM  and BFU-E  similar to  5637  CM  or 
the  purified  15-kD  protein.  Polyclonal anti-huALP  anti- 
bodies could completely neutralize the biologic activity of 
5637  CM  (10%  vol/vol),  HPLC  fraction-32  (0.1%  vol/ 
vol),  and  rALP  (10  ng/ml).  However,  the  support  of AB 
serum (1% vol/vol) on HPC growth could not be neutral- 
ized  by  polyclonal  anti-huALP  antibodies  (Fig.  6).  l<e- 
placement of serum by the serine proteinase inhibitor c~-1 
PI (2 Ixg/ml), present in serum at a concentration as high as 
25  p,M,  supported  the  growth  of both  CFU-GM  and 
BFU-E progenitors similar to rALP. c~-1 PI supported 69  --- 
20%  of CFU-GM  and  137  -+  38%  of BFU-E  growth  as 
compared to AB serum  (n  =  3).  Replacement of rALP by 
its domains ALP-D-1 or ALP-D-2, separately or in combi- 
nation at molar concentrations equivalent to rALP, showed 
that the COOH-terminal domain ALP-D-2 contained the 
active site (Fig. 7). 
Influence  of Antileukoproteinase  on  the  Suppressive  Effect  of 
Accessory  Cells  on  HPC  Growth  in  the  Absence  of  Serum. 
Monocyte- and T  lymphocyte-depleted bone marrow cells 
were  separated  with  Dynabeads  into  CD34-  cells  and  a 
population containing 80%  CD34 +  cells. Fig. 8  shows  the 
colony growth of these purified CD34 + cells in the absence 
or presence of increasing numbers  of CD34-  cells. In two 
separate experiments, it was shown that the inhibited growth 
of CFU-GM  and  BFU-E,  induced by the  CD34-  acces- 
sory cells in the absence of serum, was completely reconsh- 
tuted  by  the  addition of rALP  (100  ng/ml)  or  CM  (10% 
fraction  (f) 
1  5  i0  15  20  25  30 
HPLC  f3a  from  gel  [  I  i  i  I  I  I 
filtration  f62  SGKSFKAGVCPPKKSAQCLRYKKPECQSDW 
no digestion 
HPLC  f30+31  from gel 
filtration  f62 
HCOOH  digestion 
1  5  i0  15  20  25  30  35  40  45 
HPLC  f28  from gel  1  [  I  I  I  I  [  I  I  i 
filtration  f68+69  SGKSFKAGVCPPKKSAQCLRYKKPECQSDWQCPGKKRCCPDTCGI 
no digestion 
antileukoproteinase  1 
sequence 
50  55  60  65  70  75 
1  i  I  I  1  I 
PVDTPNPTRRKPGKCPVTYGQCLMLNP 
1  5  i0  15  20  25  30  35  40  45  50  55  60  65  70  75  80 
L  I  I  I  1  L  I  L  I  I  I  h  I  L  I  L  I 
SGKSFKAGVCPPKKSAQCLRYKKPECQSDWQCPGKKRCCPDTCGIKCLDPVDTPNPTRRKPGKCPVTYGQCLMLNPPNFC 
81  85  90  95  I00  105 
I  I  I  h  i  I 
EMDGQCKRDLKCCMGMCGKSCVSPVKA 
Figure  5.  Amino acid sequence analysis  of HPC growth-supporting fractions (f) purified from 5637-cell CM. Amino acid sequences were determined 
by Edman degradation with an on-line Applied Biosystems  477A/120A sequencer. Since cysteine residues cannot be detected unless modified, their pres- 
ence was deducted .from the absence of any detectable amino acid signal at such position. ALP sequence data are available  from EMBL/GenBank/DDBJ 
under accession numbers P03973 and P07757. 
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Figure 6.  Neutralization of colony growth with anti-huALP antibod- 
ies. Before initiation of the colony assay  AB serum (AB, 1"/, vol/vol), 5637 
CM (CM, 10% vol/vol), purified natural ALP (f-32, 0.1% vol/vol), rALP 
(10 ng/mnl) were incubated at 37~  during 2 h in the presence of control 
medium or 40 p~g of polyclonal lgG anti-huALP antibodies, sufficient to 
neutralize 400 ng ofrALP. Colony growth was expressed  as percentage of 
growth of control culture, obtained in the presence of 10% (vol/vol) AB 
serum. The number of CFU-GM and BFU-E in the control culture was 
27  and  28  per  103  cells plated, respectively. In  the presence of anti- 
huALP antibodies, colony growth supported by 5637 CM, fraction f-32 
or rALP, but not by 1% (vol/vol) AB serum, was completely neutralized. 
vol/vol).  The  proteinase  inhibitor  o~-1  PI  (2  txg/ml), 
present  in  serum  at  concentrations  of 1-2  Dg/ml,  could 
also  neutralize  the  suppression  of  both  CFU-GM  and 
BFU-E growth by CD34-  cells in the absence of serum. 
Discussion 
In  the  presence  of multiple  HGF,  insulin,  cholesterol, 
and a highly purified clinical grade source of human  albu- 
min, we observed that in vitro HPC present in monocyte- 
and T  lymphocyte-depleted bone marrow failed to prolif- 
erate and differentiate into mature colonies of myeloid and 
erythroid cells.  In contrast,  purified CD34 +  cells prolifer- 
ated in  the  absence  of human  AB  serum.  Reconstitution 
experiments  showed  that  accessory cells were  responsible 
for suppression of growth of HPC  in the absence of serum 
and that the addition of serum could restore HPC  growth. 
This study, similar to studies presented by several other in- 
vestigators (I-7),  shows  that  in the presence  of high con- 
centrations of BSA,  growth  of HPC  was  observed almost 
similar to the numbers of colonies in the presence of serum 
(data not shown).  Since BSA is usually <95-99%  pure  (8, 
9),  unidentified serum factors bound to albumin may have 
influenced  the  results.  Serum-free  CM  from  the  bladder 
carcmoma cell line 5637  could replace the need for serum 
or BSA  in  the  senfisolid medium  cultures  to  support  the 
growth of HPC from normal bone marrow. Activity-based 
purification  of this  CM  led  to  the  isolation  of a  protein 
with  a  molecular  mass  of  15  kD  (SDS-PAGE)  that  was 
identified by NH2R-terminal  sequence  analysis as ALP,  a 
potent inhibitor of leukocyte elastase. The effect of this pu- 
D-1 +D-2 
D-1 
160 
• 
CFU-GM  BFU-E 
99 
+9 
28  27 
•  • 
D-,r  136  95 
__.29  _+10 
200  150  100  50  0  50  100  150  200 
percentage  colony  growth  of rALP 
Figure 7.  Growth  support of CFU-GM and BFU-E  colonies from 
monocyte- and T lymphocyte-depleted mononuclear bone marrow cells 
in the presence of multiple HGF by proteinase inhibitors. In the ab~nce 
of sermn, the two separate domains of rALP, the NH2-terminal domain 
1)-1 and the COOH-terminal domain 1)-2 were added separately or in 
combination at molar concentrations equivalent to  rALP (100 ng/ml). 
Colony gvowth is expressed as percentage of growth supported by rALP 
(100 ng/nfl) (mean •  SE, n = 3). 
rifled ALP  on  HPC  growth  could  also  be  confirmed  by 
rALP.  Both  purified  natural  and  recombinant  ALP  sup- 
ported 100% of erythroid colony growth and >60% of the 
myeloid colony growth as compared to the control culture 
in  the presence  of 10%  AB  serum.  In addition, we could 
completely neutralize the biologic activity from 5637-CM 
and  purified  natural  ALP  with  a  polyclonal  IgG  anti- 
huALP, illustrating that ALP was the factor essential for the 
in vitro HPC growth from monocyte- and T  lymphocyte- 
depleted bone marrow cells in the presence of highly puri- 
fied  human  albumin.  ALP  is  a  107-amino  acid  cationic 
protein  consisting of two  domains  of similar architecture 
but with different inhibitory activities (18,  19). The  NH~- 
terminal domain ALP-D-1  that is assumed to bind trypsin 
could not support growth of HPC in the absence of serum. 
The COOH-temfinal domain ALP-D-2, containing a strong 
inhibitory  activity against  chymotrypsin,  neutrophil  elas- 
tase,  and  trypsin,  restored  the  colony  growth,  indicating 
that  the  proteinase  inhibitory activity of ALP  was  indeed 
responsible for the support of the HPC growth in vitro. 
ALP,  also  known  as  secretory leukocyte proteinase  in- 
hibitor,  is present  in  a  wide  variety of mucous  secretions 
and  produced by epithelial-like cells (20).  This  local pro- 
duction  of  ALP  with  very  high  affinity  for  leukocyte 
elastase serves as a potential regulatory feedback mechanism 
to prevent epithelial damage caused by proteolytic protein- 
ases (21).  Regulatory effects of ALP in hematopoiesis have 
not been described previously. Serum contains various ser- 
ine proteinase inhibitors, of which 0r  PI and o~2-macro- 
globulin are present at relatively high concentrations of 1.3 
mg/ml  and  1.7  mg/ml,  respectively  (22);  ALP  has  been 
found  to  circulate  at  a  concentration  of 5(i) ng/ml  (21). 
When serum was replaced by c~-1 PI, the roam plasma pro- 
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Figure 8.  Inhibition of the suppressive  effect of CD34- accessory cells on HPC growth of purified CD34 + cells in the absence  of serum by proteinase 
inhibitors.  In the presence of HGF,  the CD34 + cells were cultured with increasing numbers of CD34-  cells, up to a ratio  1:16 supplemented with 
IMDM, rALP (100 ng/ml), CM (10% vol/vol), AB serum (10% vol/vol), or ct-1 Pl  (2 l~g/ml). The growth of CFU-GM and BFU-E is expressed as per- 
centage of growth of control culture, obtained in the presence of 10% (vol/vol) AB serum in the absence  of CD34- cells. The results of two experiments 
(iLl and/3) are shown. 
teinase  inhibitor  of neutrophil  elastase  (22),  the  growth 
support was comparable to rALP. These results support the 
evidence that the proteinase inhibitory activity is responsi- 
ble  for  the  observed  effects.  The  high  concentrations  of 
other  serine  proteinase  inhibitors  may  explain  why  anti- 
huALP antibo :lies did not abolish the stimulatory effect of 
serum. 
Since the bone marrow accessory cells responsible for the 
suppression  of growth  of CD34-purified  HPC  were  de- 
pleted of monocytes and T  lymphocytes, the myeloid cells 
appeared to be the mediator cells  for this effect. Probably, 
these myeloid cells secrete proteolytic proteinases like neu- 
trophil  elastase  that  are  capable  of degrading  cytokines, 
growth factor receptors, or other proteins essential for the 
proliferation of HPC (23-25). ALP or other proteinase in- 
hibitors present in serum apparently neutralized these pro- 
teolytic  enzymes.  The  mechanisms  by  which  ALP  sup- 
ported the proliferation of HPC in vitro may be at the cell 
membrane level by protecting from degradation cellular re- 
ceptors or proteins in the culture medium that are essential 
for  HPC  growth.  In  conclusion,  we  demonstrated  that 
monocyte- and T  lymphocyte-depleted accessory bone mar- 
row cells suppressed the in vitro growth ofCD34 + HPC in 
the absence of serum. The serine proteinase inhibitor ALP 
was capable of restoring the proliferation of HPC in vitro 
in the presence of multiple HGF, highly purified albumin, 
insulin,  and cholesterol. These results show that proteinase 
inhibitors  are  important  for  optimal  in  vitro  growth  of 
HPC and may be essential for in vitro expansion of human 
hematopoietic stem cells in serum-free medium. 
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